Lenvatinib Mesylate CAS 857890-39-2 Intende 98.0~ 102.0% Factory

Description:

Nomen chemicum: Lenvatinib Mesylate

CAS: 857890-39-2

Pertentare: 98.0~ 102.0%

Aspectus: Alba ad Off-White vel Crystal

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4

Chemical Properties:

Nomen chemicum	Lenvatinib Mesylate
Synonyma	4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mesylate;Lenvima
CAS Number	857890-39-2
CATTUS Number	RF-PI1975
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C21H19N4O4Cl.CH4O3S
M. Pondus	522.96
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White vel Crystal
Lepidium sativum	per IR;per UV;per HPLC
Solubilitas	Leviter solutum in aqua, prope insolubile in Ethanol
Liquescens punctum	228.0~230.0℃
Aqua Content (KF)	<1.00%
Residere in Ignition	<0.10%
Metalla gravis	<20ppm
Substantiae cognatae
Unam immunditiam	<0.50%
Totalis immunditias	<1.00%
Asssay / Analysis Methodo	98.0~ 102.0% (HPLC Basis in remittit)
Mole densitas	0.40gm/ml~0.60gm/ml
Test Standard	Enterprise Standard
Consuetudinem	API

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

Lenvatinib Mesylate (CAS: 857890-39-2) est oralis et multi-iaculator inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, RET cum potentiis antitumoris actionibus.Lenvatinib Mesylate receptaculum tyrosinum kinasum (RTK) inhibitor qui selectivam habet pro VEGFR2.Activitas antineoplasticas exhibet, et aegrorum curationi localiter recurrente vel metastatico, progressivo, iodi radioactivo (RAI) - refracto-refracto differentiato cancri thyroidis indicatus est.Lenvatinib Mesylate primum probatus est ab US Cibus et Drug Administration (FDA) die 13 Feb. 2015, deinde probatus a Pharmaceuticis et Medicis machinis Agency Iaponiae (PMDA) die 26 Mar 2015 probatus est et in Medicina Europaea Agency (EMA) in 28 Maii 2015. Eisai ut Lenvima® amplificata et venales sunt.Lenvatinib Mesylate receptor tyrosinus kinasus inhibitor multiplex oralis est cum singulari ligandi modo, qui selective vetat kinasum actionis incrementi endothelialis vascularium factoris (VEGF) receptorum, praeter alios pathos proangiogenicos et oncogenicos tyrosinos kinases relatas cogitationis implicandas esse in tumore multiplicationis. .Indicatur curatione cancri thyroideae radioiodine-refractariae progressivae differentiatae.Lenvimaper se adhibetur ut cancerem thyroideum differentiatum tractaret (DTC), genus cancri thyroideum, quod iam non potest tractari cum Iodo radioactivo et progreditur.LENVIMA una cum alia medicina, quae everolimus vocatur, adultos tractare cum specie cancri renis, quae carcinoma renum processit (rcc) post unum curationem cum alia medicina anti-cancri.